Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
RESEARCH TOOLSreports
MDP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.47 - C$5.56
Previous CloseN/A
Volume43.25K
Average Volume (3M)76.56K
Market Cap
C$87.10M
Enterprise ValueC$130.64M
Total Cash (Recent Filing)$8.44M
Total Debt (Recent Filing)$39.91M
Price to Earnings (P/E)13.6
Beta0.95
Next Earnings
Jul 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding32,258,003
10 Day Avg. Volume27,692
30 Day Avg. Volume76,555
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.42
Price to Cash Flow (P/CF)2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.20
Enterprise Value/Ebitda7.07
Forecast
1Y Price Target
C$5.94Price Target Upside120.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Returns Gleolan U.S. Rights to NX Development Corp.
PremiumCompany Announcements
Medexus Launches GRAFAPEX in US, Eyes $100M Revenue
PremiumCompany Announcements
Medexus Pharmaceuticals: Robust Earnings Amidst Challenges
PremiumCompany Announcements
Medexus Secures Ontario Public Reimbursement for Trecondyv
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalU.S. FDA approves Treosulfan, marking a significant benefit to patients.
Financial PerformanceMedexus's FQ3 results were ahead of initial estimates, showing strong performance.
Bears Say
Market CompetitionThere is generic risk in the base business with Rupall losing exclusivity.
Regulatory ChallengesMedexus faces a negative Health Canada setback for Terbinafine.
---
Options Prices
Currently, No data available
---
Ownership Overview
7.37% Insiders
0.40%
Mutual Funds
0.03% Other Institutional Investors
92.19% Public Companies and
Individual Investors
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$1.47 and its highest was C$5.56 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Medexus Pharmaceuticals Inc’s market cap is C$87.10M.
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Jul 01, 2025 which is in 98 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Feb 05, 2025. The company reported C$0.043 earnings per share for the quarter, missing the consensus estimate of C$0.052 by -C$0.009.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is -0.1.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 32,258,003 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of C$0.043 in its last earnings report, missing expectations of C$0.052. Following the earnings report the stock price went down -19.525%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
---
Medexus Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$5.94 (120.00% Upside)
C$5.94 (120.00% Upside)
Insider Transactions
Bought Shares
Worth C$50.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
75.32%
12-Months-Change
Fundamentals
Return on Equity
11.27%
Trailing 12-Months
Asset Growth
-0.72%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
---
MDP Stock 12 Month Forecast
Average Price Target
C$5.94
▲(120.00% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering MDP
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+32.54%
reiterated a buy rating 2 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +32.54% per trade.
---